View Older Stories View More Recent Stories

Nov 5, 2018 06:59AM Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
Oct 25, 2018 08:15AM Halozyme Therapeutics (HALO) Reports First Clinical Dosing In Bristol-Myers Squibb (BMY) Phase 1 Trial Of BMS-986179 With Enhanze Technology
Oct 25, 2018 08:00AM Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology
Oct 25, 2018 06:59AM Bristol-Myers Squibb Reports Third Quarter Financial Results
Oct 22, 2018 06:45AM Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Results in Significantly Longer Treatment-Free Survival in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Oct 22, 2018 06:00AM Bristol-Myers Squibb (BMY) Reports Data from Phase 3 CheckMate -067 Clinical Trial for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab)
Oct 22, 2018 03:20AM Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits in Patients with Advanced Melanoma
Oct 22, 2018 03:15AM Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer
Oct 20, 2018 03:15AM Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Shows Promising Results in Patients with Advanced Form of Bladder Cancer
Oct 19, 2018 04:17PM Bristol-Myers Squibb (BMY) Provides Update on Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy
Oct 19, 2018 04:16PM Bristol-Myers Squibb Provides Update on the Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Patients with Tumor Mutational Burden ≥10 mut/Mb
Oct 17, 2018 06:59AM Bristol-Myers Squibb to Showcase Immunoscience Research and Biomarker-Guided Treatment Approaches at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annu
Oct 12, 2018 07:00AM Bristol-Myers Squibb (BMY) Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of OS with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed SCLC
Oct 12, 2018 06:59AM Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of Overall Survival with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed Small Cell L
Oct 11, 2018 07:00AM Bristol-Myers Squibb (BMY) and Compugen (CGEN) Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors
Oct 11, 2018 06:59AM Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors
Oct 11, 2018 06:59AM Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors
Sep 18, 2018 07:12AM Bristol-Myers Squibb (BMY) Announces EMA Validates its Application for Empliciti Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma
Sep 18, 2018 06:59AM European Medicines Agency Validates Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma
Sep 18, 2018 06:59AM European Medicines Agency Validates Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma
Sep 13, 2018 01:05PM Natera (NTRA) Enters Agreement with Bristol-Myers (BMY) for Signatera ctDNA Assay
Sep 12, 2018 04:10PM Bristol-Myers Squibb Announces Dividend
Sep 12, 2018 05:59AM Bristol-Myers Squibb (BMY) Reports 'Significant Skin Clearance' from Phase 2 Study of BMS-986165 in Patients with Moderate to Severe Plaque Psoriasis
Sep 12, 2018 02:01AM Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial
Sep 6, 2018 03:00PM Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
Sep 6, 2018 06:59AM Bristol-Myers Squibb to Announce Results for Third Quarter 2018 on October 25
Sep 5, 2018 06:59AM Bristol-Myers Squibb Kicks Off Coast 2 Coast 4 Cancer Ride to Fundraise for the V Foundation for Cancer Research
Aug 30, 2018 07:01AM Bristol-Myers Squibb (BMY) Reports FDA Approval of Supplemental Biologics License Application for Sprycel (dasatinib) in Pediatric Patients
Aug 30, 2018 06:59AM U.S. Food and Drug Administration Accepts Bristol-Myers Squibb’s Application for Sprycel (dasatinib) in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
Aug 28, 2018 09:00AM Bristol-Myers Squibb Appoints Christopher Boerner Executive Vice President and Chief Commercial Officer
Aug 23, 2018 07:00AM Bristol-Myers Squibb (BMY) Says FDA Accepts for Priority Review of its Application for Empliciti Plus Pomalidomide and Low-Dose Dexamethasone in Patients with RRMM
Aug 23, 2018 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed or
Aug 17, 2018 07:00AM Bristol-Myers Squibb (BMY) Says FDA Approved Opdivo as First New Medication in Nearly 20 Years for Certain Patients with Previously Treated SCLC
Aug 17, 2018 06:59AM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as the First New Medication in Nearly 20 Years for Certain Patients with Previously Treated Small Cell Lung Cancer
Jul 31, 2018 07:00AM Bristol-Myers Squibb (BMY) Reports EMA Approval for Opdivo (nivolumab)
Jul 31, 2018 06:59AM European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Under
Jul 26, 2018 06:59AM Bristol-Myers Squibb Reports Second Quarter Financial Results
Jul 24, 2018 07:00AM Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer
Jul 23, 2018 08:30AM Bristol-Myers Squibb Announces Departure of Chief Commercial Officer
Jul 19, 2018 07:13AM Bristol-Myers Squibb (BMY) Reports Clinical Research Collaboration with Gritstone Oncology to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors
Jul 19, 2018 07:00AM Bristol-Myers Squibb and Gritstone Oncology Announce Clinical Research Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors
Jul 11, 2018 07:00AM Bristol-Myers Squibb (BMY) Opdivo + Low-Dose Yervoy is First Immuno-Oncology Combination Approved for Some MSI-H/dMMR mCRC Patients
Jul 11, 2018 06:59AM Bristol-Myers Squibb’s Opdivo® (nivolumab) + Low-Dose Yervoy® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a
Jul 5, 2018 07:00AM Bristol-Myers Squibb (BMY) Says EC Approved Expanded Indication for Sprycel
Jul 5, 2018 06:59AM European Commission Approves Expanded Indication for Sprycel (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Jun 29, 2018 07:54AM Bristol-Myers Squibb (BMY) Announces Positive CHMP Opinion Recommending Approval of Opdivo for Adjuvant Treatment of Adult Patients with Melanoma
Jun 29, 2018 07:54AM Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma
Jun 21, 2018 04:20PM Bristol-Myers Squibb (BMY) Reports FDA Acceptance of Supplemental Biologics License Application for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab)
Jun 21, 2018 04:15PM U.S. Food and Drug Administration (FDA) Accepts Application for Opdivo Plus Low-Dose Yervoy for Treatment of First-Line Non-Small Cell Lung Cancer in Patients with Tumor Mutational Burden ≥10 mut/Mb
Jun 20, 2018 06:59AM Dallas Cowboys Quarterback Dak Prescott, Modern Family Star Eric Stonestreet and Actress Tia Mowry Call on Americans to Rise Up Against Cancer Through Ready. Raise. Rise.
View More Recent Stories View Older Stories